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Abstract
Background: Acute bronchiolitis is the commonest cause of hospitalisation in infancy. Currently management
consists of supportive care and oxygen. A Cochrane review concluded that, “nebulised 3 % saline may significantly
reduce the length of hospital stay”. We conducted a systematic review of controlled trials of nebulised hypertonic
saline (HS) for infants hospitalised with primary acute bronchiolitis.
Methods: Searches to January 2015 involved: Cochrane Central Register of Controlled Trials; Ovid MEDLINE;
Embase; Google Scholar; Web of Science; and, a variety of trials registers. We hand searched Chest, Paediatrics and
Journal of Paediatrics on 14 January 2015. Reference lists of eligible trial publications were checked. Randomised or
quasi-randomised trials which compared HS versus either normal saline (+/− adjunct treatment) or no treatment
were included. Eligible studies involved children less than 2 years old hospitalised due to the first episode of acute
bronchiolitis. Two reviewers extracted data to calculate mean differences (MD) and 95 % Confidence Intervals (CIs)
for length of hospital stay (LoS—primary outcome), Clinical Severity Score (CSS) and Serious Adverse Events (SAEs).
Meta-analysis was undertaken using a fixed effect model, supplemented with additional sensitivity analyses. We
investigated statistical heterogeneity using I2. Risk of bias, within and between studies, was assessed using the
Cochrane tool, an outcome reporting bias checklist and a funnel plot.
Results: Fifteen trials were included in the systematic review (n = 1922), HS reduced mean LoS by 0.36, (95 % CI
0.50 to 0.22) days, but with considerable heterogeneity (I2 = 78 %) and sensitivity to alternative analysis methods. A
reduction in CSS was observed where assessed [n = 516; MD −1.36, CI −1.52, −1.20]. One trial reported one possible
intervention related SAE, no other studies described intervention related SAEs.
Conclusions: There is disparity between the overall combined effect on LoS as compared with the negative results
from the largest and most precise trials. Together with high levels of heterogeneity, this means that neither individual
trials nor pooled estimates provide a firm evidence-base for routine use of HS in inpatient acute bronchiolitis.
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Background
Acute bronchiolitis is the most common cause for hospi-
talisation in infancy and childhood, with 1–3 % of all
infants admitted to hospital during their first winter [1–9].
Obstruction of the airways results in severe breathing diffi-
culties caused by common respiratory viruses infecting the
lungs [1–8, 10–13]. The peak age of incidence is between
1 and 6 months for babies admitted with this condition
[9]. Current management involves supportive care, min-
imal handling, supplemental oxygen and fluids [4, 14–16].
The median duration of admission is 3 days, considerably
higher than for other acute paediatric admissions (median
1 day). The course of the illness or length of hospital
stay has not been impacted by treatments including oral
and inhaled steroids, antiviral agents and a variety of
bronchodilators.
A number of small studies have suggested that nebulised
hypertonic saline may influence the course of the illness
resulting in a reduction in the duration of hospitalisation
for infants admitted with “acute bronchiolitis” [17–20]. A
Cochrane review, which last updated its searches in May
2013, included 11 trials involving 1090 infants with mild
to moderate acute viral bronchiolitis (500 inpatients, six
trials; 65 outpatients, one trial; and 525 emergency depart-
ment patients, four trials) [21]. The review concluded that
“current evidence suggests nebulized 3 % saline may sig-
nificantly reduce the length of hospital stay and improve
the clinical severity score in infants with acute viral bron-
chiolitis.” Our team felt that this conclusion is difficult to
justify on two counts. Firstly, the findings are hampered
by high levels of heterogeneity, and we believe these war-
rant further exploration. Secondly, a number of relevant
published trials, published at the time appear to have been
overlooked; this is still the case as of the 2013 update.
Finally, since 2013, a number of large studies addressing
this topic have been published.
As a result, we made a registration on the PROS-
PERO database and undertook a separate systematic
review on the effect of hypertonic saline on the length
of stay of infants admitted to hospital for acute
bronchiolitis. The PROSPERO protocol is available
(Additional file 1). This review does not investigate the
use of hypertonic saline in infants with bronchiolitis in
the emergency department.
Methods
This study is reported in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidance [22]. A checklist
is available (Additional file 2). Since this study was a
literature review of previously reported studies, ethical
approval or additional consent from participants was
not required.
Protocol and registration
The protocol was registered with the PROSPERO data-
base (CRD42014007569) [23] on 03 March 14 and the
registration was updated on 18 December 2014.
Eligibility criteria
We included published and unpublished randomised
controlled trials involving children up to the age of
2 years, hospitalised as the result of a first episode of
acute bronchiolitis. Trials were included if hypertonic
saline versus either normal saline (+/− adjunct treat-
ment) or no treatment were the interventions. Studies
were grouped in pre-specified subgroups as follows: (1)
Nebulised hypertonic saline alone vs normal saline; (2)
Nebulised hypertonic saline plus a bronchodilator (e.g.
salbutamol) vs. normal saline; (3) Nebulised hypertonic
saline plus a bronchodilator vs. normal saline plus same
bronchodilator; (4) Nebulised hypertonic saline alone or
plus a bronchodilator vs. no intervention. We applied
no restrictions based on the concentration, dose or
administration of the intervention or control. We
excluded studies not published in English.
Literature search and information sources
We searched Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE (via Ovid), EMBASE
from inception to January 2015, Web of Science from
2010 to January 2015 and Google Scholar. We used
2010 as a cut off, the date on which Zhang and col-
leagues ran their searches for the 2011 update [24]. We
used the terms “bronchiolitis” and “hypertonic saline”
to identify ongoing unpublished data in the following
registries: Clinicaltrials.gov; UK Clinical Trials Gateway
(UKCTG); CRD databases (DARE NHS EED, HTA);
controlled-trials.com; centrewatch.com and National
Research Register (NNR). On 14th January 2015 we also
hand-searched Chest, Paediatrics and Journal of Paedi-
atrics using the terms “hypertonic saline” and “bron-
chiolitis”. One reviewer (HC) checked the reference lists
of all eligible trial publications for other relevant trials.
The final search strategy is outlined in Additional file 3.
Study selection
Two reviewers (CM and HC) independently assessed eligi-
bility, differences were resolved through discussion with
third reviewers (DH and ME). Where the titles or abstracts
suggested eligibility, we retrieved and screened the full
paper. Unsuccessful attempts were made to contact trial
investigators of three unpublished studies [25–27] to
request additional unreported data.
Data extraction
CM and HC used a standardised data collection tool to
include study characteristics, population characteristics
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and risk of bias [28]. Population and study data com-
prised of country where the trial was conducted, age,
disease severity, intervention and comparator details
(concentration, dose, delivery mechanism), and details of
any adjunct treatments given (β2 agonist or epinephrine).
We extracted baseline and follow-up outcome data for
Length of hospital stay (LoS), final Clinical Severity
Scores (CSS) using the scoring system described by
Wang and colleagues [29], readmission rate and adverse
events. Adverse event data was collected however re-
ported but of particular interest were tachycardia, hyper-
tension, pallor, tremor, nausea, vomiting and acute
urinary retention. DH helped resolve any discrepancies
with any of the data items.
Risk of bias
We separately assessed the potential for systematic error
within individual studies using the Cochrane risk of bias
tool [30] and the following dimensions of methodological
quality: (1) generation of allocation sequence; (2) allocation
concealment; (3) blinding (participant and researchers); (4)
blinding of outcome assessors; (5) completeness of out-
come data; (6) selective outcome reporting. Studies were
grade as being at, “low”, “high” or “unclear” risk of bias.
Any discrepancies were discussed between the data extrac-
tors until both reached a unanimous decision. Where an
unclear grading was given we contacted trial authors to
obtain further information and searched for the study
protocol to identify sources of reporting bias. We used
standard methods (based on the Cochrane Handbook) to
assess funnel plot symmetry as we had greater than 10
trials in the meta-analysis [30]. We employed methods sug-
gested by Dwan and colleagues [31] to assess the risk of
outcome reporting bias for each of the outcomes using the
Outcome Reporting Bias (ORB) classification whereby
trials are scored as “high risk”, “low risk” or “partial risk”.
The full classification table is available in Additional file 4.
Synthesis
The primary outcome was LoS. Secondary outcomes were
adverse events, final CSS scores and rate of readmission.
Data on LoS and final mean CSS was used to calculate
mean differences (MD) with 95 % Confidence Intervals
(CIs) for each outcome. Where trials included arms using
different concentrations of hypertonic saline in addition to
a control arm we treated them as two separate trials, div-
iding the control arm numbers by two in order not to
double-count control participants. Meta-analyses were
undertaken in RevMan Version 5.2 and Stata version12
using both fixed (Inverse-Variance) and random effect
(Der Simonian & Laird) models [32]; additional sensitivity
analyses used the metasens package as implemented
within the R software version 3.1.3[33]. The four pre-
specified intervention subgroups were separated in the
main forest plot to give subgroup estimates of treatment
effects. Statistical heterogeneity—a measure of within-
trial variation—was investigated using the I2 statistic
[30]: 0–40 % indicating unimportant levels; 30–60 %
showing moderate heterogeneity; 50–100 % as demon-
strable heterogeneity within trials. Sensitivity analyses
were undertaken as proposed by Deschartres et al. [34]
along with meta-regression to assess whether heterogeneity
could be attributed to measurable sources. An assessment
for the potential of publication bias was made via assess-
ment of the funnel plot generated for all trials included in
the meta-analysis. We produced a narrative description of
adverse events and readmission rates.
Results
Searches and selection
After removal of duplicates, the searches yielded 1489
citations, from which 1443 were excluded at the title/
abstract stage (Fig. 1). We retrieved 46 full papers for
further review of which 28 were excluded because they
were not a controlled trial (n = 4) [35–38], were in the
wrong setting (n = 7) [39–45] or wrong population or
intervention (n = 15) [17, 46–59], or were not available
in English (n = 2) [60, 61]. All included studies were
parallel group, participant-randomised trials. 3 were
multi-centre; 9 were single centre and the number of
centres was unknown for 6. We identified 18 trials (2225
participants, excluding one trial as the number of partici-
pants is unknown [26]) eligible for inclusion at the full
paper review stage (Fig. 1). Details of all excluded trials at
the full stage can be found in Additional file 5.
Study characteristics
The remaining 18 trials (total number of children in-
cluded in the analysis) were conducted in: Italy (n = 106)
[62]; United Arab Emirates and Canada (n = 91) [20];
China (n = 205) [63, 64]; Israel (n = 93) [18, 19];
Argentina (n = 82) [25]; India (n = 388) [65–67]; Qatar
(n = 171) [68]; Georgia (n = 42) [69]; The Netherlands
(n = 247) [70]; USA (n = 190) [71]; Turkey (n = 69) [27];
Mexico (n = unknown) [26]; Nepal (n = 59) [72] and UK
(n = 290) [73] (Additional file 6). The sample size ranged
from 40 [67] to 317 [73] participants. Eligibility criteria
varied significantly in terms of patient characteristics
and disease severity (Additional file 7). The upper age
limit for subjects ranged from 12 to 24 months. Amongst
the range of clinical characteristics required for inclusion
were ‘bronchiolitis with temperature >38 °C’, ‘first episode
of wheezing with evidence of viral infection’, ‘wheezing’,
‘wheeze and/or crackles’, ‘crackles’, and ‘first episode of
bronchiolitis’. In terms of severity, oxygen saturation in air
was specified in 4 studies and ranged from <97 to <92 %.
Numbers of participants allocated to each group was
clearly defined in all but three trials [26, 27, 69] whose
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Fig. 1 Study flow diagram
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data was not usable in the meta-analysis as attempts to
contact the author were fruitless.
Population characteristics
The average age ranged from 2.6 months [19] to
8.6 months (median = 4.5 months). Five studies including
children under 12 months age only [18, 19, 65, 70, 72].
The heterogeneity of study design and patient populations
was emphasised by the indicators of disease severity at
entry to the study. Baseline oxygen saturations were re-
ported in nine studies [18–20, 62, 65, 66, 68, 70, 72]; these
ranged from very mild (SaO2 of 90.5 % [64]) to significant
respiratory compromise (SaO2 of 97.4 % [68]). Clinical
scoring systems were used to classify disease severity
in 15 of 18 studies [18–20, 26, 27, 62–68, 70–72].
Based on the scores at entry, the disease severity var-
ied from mild/moderate [n = 5] [27, 63, 67, 69, 70],
moderate [n = 5] [18–20, 25, 65],moderate to severe
[n = 4] [26, 64, 66, 68] and severe [n = 2] [62, 73] con-
firming the heterogeneity of disease severity across
the studies. A severity classification was not provided for
Ojha et al. and Silver et al. [71, 72], but based on their char-
acteristics were subjectively classified “severe” and “mild/
moderate” respectively. Disease severity was assessed in
fifteen of the 18 trials using a variety of scoring systems to
characterise participants as “mild”, “moderate” or “severe”
or a combination of each; Wang et al. CSS scoring system
[29] (n = 8) [18, 19, 62–65, 67, 70], Respiratory Distress
Assessment Instrument (RDAI) score (n = 3) [20, 66, 71],
Bronchiolitis Severity Score (n = 1) [68], Bronchiolitis
Clinical Score (n = 1) [69], Respiratory assessment score
(n = 1) [27], Respiratory Distress Scale Sant Joan de Deu
Hospital (n = 1) [26] and Clinical scoring of respiratory
distress (n = 1) [72] (Table 1).
Intervention characteristics
All trials administered 3 % hypertonic saline via a nebu-
liser as the active intervention; three trials were designed
with an additional arm using higher concentrations of
hypertonic saline at 5 % [27, 68] or 6 % [70]. Fifteen of the
eighteen trials stated the amount of hypertonic saline
administered which ranged from 3 ml [25, 67] to 4 ml
[18–20, 26, 63–66, 70–73] or in one trial 5 ml [68]. Four
trials compared hypertonic saline versus normal saline
alone [20, 64, 71, 72] or versus standard care [73] with
no additional treatments. Where the flow rate was
stated (n = 10) it ranged between 5 and 10 L/min
[18, 19, 62, 65–68, 70, 71, 73]. Investigators in the
other trials administered different adjunct treatments
alongside hypertonic saline: five trials administered epi-
nephrine/adrenaline [18, 19, 62, 66, 68]; seven administered
a β2 agonist (salbutamol, albuterol) [25–27, 63, 65, 67, 70];
one trial did not specify any additional medication [69] and
five trials did not administer different adjunct treatments
alongside hypertonic saline [20, 64, 71–73].
Comparator characteristics
The majority of trials stated that they administered
0.9 % of normal saline as the control group except one
where “oxygen therapy plus best supportive care” was
the control [73] or where authors did not state the con-
centration of normal saline [67, 69]. Eight of the trials
gave oxygen therapy in both the intervention and con-
trol arms [20, 62, 64, 65, 67, 68, 70, 73], nine trials did
not specify whether oxygen therapy was provided [18,
19, 25–27, 63, 69, 71, 72] and one trial stated oxygen
therapy was provided in the intervention arm but did not
state whether this was provided in the control arm [66].
The flow rate of the nebulisers in the control groups
matched those in the intervention arm of each trial.
Risk of bias
The risk of bias was variable across studies (Additional
file 8 and Fig. 2). Eleven trials had clearly adequate allo-
cation concealment, using pharmacy to prepare and
administer solutions [20, 62], sequential identical con-
tainers [19, 65, 70], using both these methods [72], a
web-based randomisation system [71, 73] or sealed,
opaque envelopes [64, 66, 68]. Randomisation was
adequately described in eleven trials based on lists gen-
erated by computer systems or computer generated
random number tables [19, 20, 62, 64–68, 71–73]. Par-
ticipants and investigators were blinded to the treat-
ment given again in fourteen of the 18 studies; three
trials were “open label” [25, 66, 73] and one gave no de-
scription of blinding [65]. Blinding of the outcome
assessor for the primary outcome was adequately de-
scribed with the attending physician who made the de-
cision to discharge blinded in five studies [18, 19, 63,
64, 71] and all medical staff, participants and staff
blinded in one trial [70]. Participant withdrawal and the
use of intention to treat analysis were clearly explained
in all but five trials [25–27, 68, 69].
We graded two of these as being at high risk of bias:
one provided no explanation regarding the uneven dis-
tribution of withdrawals [25] and one did not state
which arms the 16 patients were excluded from [68].
The median loss to-follow-up at the time of the primary
outcome assessment (LoS) was 8 % (range 0 % [20, 63,
66, 67] to 18 % [25, 72]; twelve studies did not complete
an intention to treat analysis, presenting instead an
‘available case analysis’ for only those participants for
whom a LoS could be identified [18–20, 25, 62, 64, 65,
68, 70–73]. Three studies completed a full analysis on all
participants randomised [63, 66, 67].
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Table 1 Population characteristics
Study Age—mean (SD) Gender Disease
severity
Length of hospital
stay mean (SD) (days)
Final CSS score
Al-Ansari 2010 et al. [68] Intervention (3 % HS):
3.84 (2.84)
Intervention (3 % HS):
F19 M39
Moderate to
severe
Intervention
(3 % HS): 1.4 (1.41)
NR
Intervention (5 % HS):
4.02 (2.56)
Intervention (5 % HS):
F26 M31
Intervention (5 % HS):
1.56 (1.38)
Control: 3.30 (2.43) Control: F26 M31 Control: 1.88 (1.76)
Espelt et al. 2012 [25] NR Intervention: F24 M26 Moderate Intervention: 5.8 (2.7) NR
Control: F26 M24 Control: 5.47 (2.1)
Everard et al. 2014 [73] Intervention: 3.3 (2.6) Intervention: F69 M73 Severe Intervention: 4.19 (3.20) NR
Control: 3.4 (2.8) Control: F64 M85 Control: 4.22 (3.52)
Giudice et al. 2012 [62] Intervention: 4.8 (2.3) Intervention: F18 M34 Severe Intervention: 4.9 (1.3) Intervention: 6.5 (1.6)
Control: 4.2 (1.6) Control:F19 M35 Control: 5.6 (1.6) Control: 7.7 (1.6)
Kuzik et al. 2007 [20] Intervention: 4.4 (3.7) Intervention: F20 M27 Moderate Intervention: 2.6 (1.9) NR
Control: 4.6 (4.7) Control: F19 M30 Control: 3.5 (2.9)
Luo et al. 2010 [63] Intervention: 6.0 (4.3) NR Mild to Intervention: 6 (1.2) Intervention: 1.5 (0.5)
Control: 5.6 (4.5) moderate Control: 7.4 (1.5) Control: 2.9 (0.7)
Luo et al. 2011 [64] Intervention: 5.9 (4.1) NR Moderate to
severe
Intervention: 4.8 (1.2) Intervention: 1.7 (0.6)
Control: 5.8 (4.3) Control: 6.4 (1.4) Control: 3.1 (0.7)
Maheshkumar et al.
2013 [67]
NR NR Mild to
moderate
Intervention: 2.25 (0.89) NR
Control: 2.88 (1.76)
Mandelberg et al.
2003 [18]
Intervention: 3 (1.2) Intervention: F12 M15 Moderate Intervention: 3 (1.2) NR
Control: 2.6 (1.9) Control: F9 M15 Control: 4 (1.9)
Nemsadze et al.
2013 [69]
NR NR Mild to
moderate
Intervention: 4.4 (1.1) NR
Control: 4.9 (1.2)
Ojha et al. 2014 [72] Intervention: 8.61 (5.74) NR NR Intervention: 1.87 (0.96) NR
Control: 8.51 (4.24) Control: 1.82 (1.18)
Ozdogan et al. 2014 [27] Overall: 7.1 (5.48) NR Mild to
moderate
NR NR
Pandit et al. 2013 [66] NR NR Moderate to
severe
Intervention: 3.92 (1.72) NR
Control: 4.08 (1.90)
Sharma et al. 2013 [65] Intervention: 4.93 (4.31) Intervention: F28 M97 Moderate Intervention: 2.64 (0.88) NR
Control: 4.18 (4.24) Control: F31 M92 Control: 2.66 (0.93)
Silver et al. 2014 [71] Intervention: 3.86 (3.01) Intervention (3%HS):
F31 M62
NR Intervention: 2.49 (1.64) NR
Control: 4.39 (2.95) Control: F37 M60 Control: 2.47 (1.76)
Sosa-Bustamante et al.
2014 [26]
NR NR Moderate to
severe
NR NR
Tal et al. 2006 [19] Intervention: 2.8 (1.2) Intervention: F11 M10 Moderate Intervention: 2.6 (1.4) Intervention: 5.35 (1.3)
Control:2.3 (0.7) Control: F7 M13 Control: 3.5 (1.7) Control: 6.45 (1)
Teunissen et al. 2014 [70] Intervention (3 % HS):
3.6 (5.2)
Intervention (3 % HS):
F40 M44
Mild to
moderate
Intervention (3 % HS):
3.43 (2.24)
Intervention (3 % HS):
3.87 (3.15)
Intervention (6 % HS):
3.4 (3.8)
Intervention (6 % HS):
F35 M48
Intervention (6 % HS):
3.74 (2.99)
Intervention (6 % HS):
5.16 (4.20)
Control: 3.6 (5.0) Control: F31 M49 Control: 2.82 (2.25) Control: 4.61(5.38)
F Female, M male, NR Not reported, HS Hypertonic saline
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Fig. 2 Risk of bias
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Results and synthesis
Data from three studies [26, 27, 69] could not be included
in the analysis of the primary outcome (LoS) because it
was unclear how many participants were randomised to
each study arm or the mean and SD LoS was unavailable;
attempts to contact the authors failed. Twelve trials pre-
sented available case analyses for the primary outcome,
LoS, and the denominators for these trials express the
number analysed, rather than the number randomised
(Figs. 3 and 4) [18–20, 25, 62, 64, 65, 68, 70–73].
Across fifteen studies (n = 1922 participants), hyper-
tonic saline, compared with any comparator, reduced
mean LoS by approximately a third of a day using a
fixed effect approach [mean difference = −0.36, 95 %
CI −0.50 to −0.22 days; Fig. 3]. Reflecting the high levels
of statistical heterogeneity (I2 = 78 %) a random-effects
analysis was undertaken: this gave a pooled effect size
of −0.44 (−0.14 to −0.74) The between-trials variance
(τ2 = 0.27) can be used to derive a prediction interval
for the of effect size in a future: this ranged from −1.59
to +0.71. [74] The results are presented in (pre-speci-
fied) subgroups based on standard care, but consider-
able heterogeneity remains even within these. The
funnel plot for LoS was not classically symmetrical, but
neither was it suggestive of publication bias or small
study effects (see Fig. 5).
To further explore the heterogeneity we performed
sensitivity analyses. Firstly, the contribution of each
study to the overall effect size and heterogeneity were
assessed graphically by constructing a Baujat plot (Fig. 6)
[75]. The figure shows, for each trial, the impact of ex-
cluding it from the final analysis (vertical axis), plotted
against its contribution to the heterogeneity statistic
(horizontal axis). As a general guide, with homogeneity
the contribution to heterogeneity (horizontal axis) should
range between approx. 0–5 for each study. Two studies
are clear outliers, contributing excessively to the hetero-
geneity [63, 64]; a third contributes to both heterogeneity
and effect size, which is to be expected given it contains
38 % of the overall weight [65].
Fig. 3 Difference in length of hospital stay by intervention subgroup, 3 % hypertonic saline
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Fig. 4 Difference in length of stay by intervention subgroup, all concentrations of hypertonic saline
Fig. 5 Funnel plot, difference in length of hospital stay (whole group)
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Secondly, we reproduce the approach taken by
Dechartres [34] in which the original analyses are
compared to those derived from i) the single most
precise trial (the trial with the narrowest confidence
interval [65]); ii) the pooled average of largest 25 %
of trials; iii) the beta0 limit-analysis proposed by
Rücker et al. (2011) to control for small-study effects
[76]; and iv) restricted to trials at low overall risk of bias.
For the latter, we undertook two analyses, the first allow-
ing unblinded trials which were otherwise considered low
RoB, and the second limiting to blinded low RoB trials.
These secondary analyses are depicted in Fig. 7. Lastly, we
repeated the analyses excluding the two outlying trials
identified above [63, 64]. The resulting analyses exhibit
considerable disparities. The overall results are contra-
dicted by the largest and most precise trials, both of which
estimate virtually no difference between the groups. Ex-
cluding the two Luo trials greatly reduces the heterogen-
eity with the overall I2 falling from 75 to 23 % and the
overall effect size reduced to a more modest (albeit statis-
tically significant) difference of 3.8 h (I-V analysis; 95 % CI
0.2 to 7.2 h) or 5.0 h (D&L analysis; 95 % CI 0.2 to 9.6 h).
Lastly we used meta-regression to explore whether any
of the sources of heterogeneity could explain the incon-
sistency (Fig. 8). Specifically, we assessed the relationship
between the effect sizes observed within each trial against
its i) mean age; ii) mean baseline oxygen saturation; and
iii) severity classification. None of the associations were
statistically significant and, more importantly, the residual
heterogeneity statistics (ie variation remaining after adjust-
ment) was virtually unchanged, indicating the between-
trial variation was not well explained by any of the three
characteristics explored.
Five trials contributed to the mean difference in final
CSS scores (n = 516, MD −1.36 (95 % CI −1.52 to −1.20);
we observed no statistical heterogeneity [19, 62–64, 70].
One trial reported one SAE possibly related to the inter-
vention [73], no other studies described intervention
related SAE’s.
In an analysis of three studies that reported readmission
rate [68, 71, 73] (651 participants), no difference was
observed between hypertonic saline and control [RR 0.90,
95 % CI 0.52 to 1.55]; there was no statistical heterogen-
eity (I2 = 0 %). A decision was made not to attempt a
meta-analysis of adverse event data which, where reported,
was mainly narrative and not consistently captured across
trials. We present a narrative summary in Additional file 9.
One study described one SAE, of bradycardia and desatur-
ation during administration of the nebuliser, which had
resolved by the following day [73], no other studies
described any serious adverse events related to the inter-
vention of hypertonic saline.
Fig. 6 Baujat plot comparing weight to overall heterogeneity
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Fig. 8 Meta-regression investigating age, baseline oxygen saturation, and severity classification as sources of heterogeneity
Fig. 7 Sensitivity analyses based on precision, size, small study effects and risk of bias
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Discussion
Summary of findings
Overall hypertonic saline was associated with a reduced
length of stay, with a pooled difference of −0.36, [95 %
CI −0.50 to −0.22]. The evidence for this result is of
moderate varies quality (GRADE summary of findings in
Table 2). However, our confidence in this estimate is
undermined by the excessive heterogeneity of the results
(I2 = 78 %) and inconsistency between the main and
sensitivity analysis in general. Of particular note is that
the overall pooled estimate is contradicted by the four
largest component trials [65, 70, 71, 73], all of which
found no benefit of hypertonic saline. The true impact
of hypertonic saline therefore appears to depend greatly
on the patient population within which each trial was
conducted, and in particular the level of standard care.
Strengths and limitations of the findings
High levels of statistical heterogeneity associated with
the meta-analysis dominate the results making their
interpretation challenging. The addition of concomitant
medications may explain some of this heterogeneity
across intervention subgroups, with as the largest effect
sizes found in trials where hypertonic saline was given
alone. Studies were conducted across a number of differ-
ent healthcare settings with diverse local services, usual
care, guidelines (e.g. definition of “fit to discharge”) and
disease severity at entry, all of which must contribute to
the extensive intra-trial variation observed. That many of
the largest trials contributed such little weight to the ana-
lysis undermines our confidence in the results. Further-
more, the absence of re-admission rate in the majority of
trials may suggest the intervention is not as economically
beneficial as the results suggest.
A key strength is the inclusion of 15 of the 18 trials in
the meta-analysis of the primary outcome. This facilitated
both investigation of publication bias and allowed for
subgroup analyses and aggregate data meta-regression,
although there was incomplete data in relation to second-
ary outcomes and trial design features.
One can argue the potential of publication bias based
on the uncharacteristic funnel plot shape. Systematic
error is not thought to always be caused by application
of language restrictions to meta-analyses despite the
potential reduction of the precision of pooled estimates
[77]. Nonetheless, restriction of trials to only English
Table 2 Summary of findings table
Assumed risk Corresponding risk Relative effect
(95 % CI)
No of Participants
(studies)
Quality of
the evidence
(GRADE)
Outcomes Normal saline (+/− adjunct
treatment) or oxygen
therapy plus best
supportive care
Hypertonic saline
(+/− adjunct treatment)
Hypertonic saline
versus normal saline
alone (days)
The mean length of
hospital stay ranged
across control groups
from 1.82 to 6.4 days
The mean length of
hospital stay ranged
across hypertonic
saline groups from
1.87 to 4.8 days
0.58 (95 % CI −0.86
to −0.30) days
452 (4 inpatient trials) ⊕⊕⊕⊕
higha
Hypertonic saline plus B2
agonist vs normal saline
plus B2 agonist (days)
The mean length of
hospital stay ranged
across control groups
from 2.66 to 7.4 days
The mean length of
hospital stay ranged
across hypertonic saline
groups from 2.25 to 6 days
0.18 (95 % CI −0.36
to 0.01 days)
710 (5 inpatient trials) ⊕⊕⊕⊖
moderateb
Hypertonic saline plus
epinepherine vs normal
saline plus epinephrine (days)
The mean length of
hospital stay ranged
across control groups
from 1.88 to 5.6 days
The mean length of
hospital stay ranged
across hypertonic saline
groups from 1.4 to 4.9 days
0.56 (95 % CI −0.86
to −0.27 days)
470 (5 inpatient trials) ⊕⊕⊕⊕
highc
Hypertonic saline alone or plus
bronchodilator versus no
intervention (days)
The mean length of
hospital stay for control
groups was 3.7 days
The mean length of
hospital stay in the
hypertonic saline
group was 3.7 days
0.07 (95 % CI −0.61
to 0.27 days)
290 (1 inpatient trial) ⊕⊕⊕⊖
moderated
The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95 % confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95 % CI)
CI Confidence interval; RR Risk Ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low quality: We are very uncertain about the estimate
aSubstantial heterogeneity; all studies double blinded and generally low risk of bias
bSubstantial heterogeneity; one study had incomplete outcome data and was un-blinded
cNo heterogeneity; one study had incomplete outcome data and one was un-blinded
dSingle study, no blinding
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articles may have altered the precision, effect size,
heterogeneity and overall risk of bias.
Summary of heterogeneity
In undertaking this systematic review it has become appar-
ent that there are a number of semantic, methodological
and cultural differences across the studies, all of which im-
pacts on the results obtained and the generalisability of an
individual trial’s findings. We propose some of these factors
below, and offer an explanation for how these may impact
on the interpretation of the review’s findings.
i) The definition of ‘acute bronchiolitis’ differs between
countries, and indeed across clinicians in the same
institution. Inevitably this diversity was reflected in the
description of infants included which variously
specified wheeze and or crackles (n = 4) [20, 68, 70, 73];
a first episode of wheezing (n = 5) [62–66];
“bronchiolitis” (n = 4) [19, 67, 71, 72]; or bronchiolitis
with a temperature >38C (n = 1) [18]; while
information was absent in four others [25–27, 69]. The
term “wheeze” is itself open to interpretation (and
sometimes misinterpretation) within the medical
profession [78–82], and may be taken to include
children presenting with their first exacerbation of
asthma, and manifesting as bronchospasm. The
occurrence of this is less common among younger
patients, and as a consequence we may have expected
the effect size to vary according to the mean age of the
study population. Nevertheless, our meta-regression to
investigate this was equivocal.
A more immediate explanation is that the impact of
HS varied with severity. All patients included in this
study met the definition of acute bronchiolitis as used in
the UK, Australia and parts of Europe which in sum-
mary involves apparent viral infection, signs of lower
respiratory tract disease with airflow obstruction mani-
fest by increased work of breathing, hyperinflation of the
chest and widespread crackles, with or without intermit-
tent wheeze. Clearly there are considerable differences in
setting and in the types of patients included in different
studies.
ii) Variation among discharge criteria
The consistency of the outcomes—specifically ‘length
of stay’ and ‘fit for discharge’—is self-evidently defined
and assessed in very different ways across the studies.
Moustgaard et al. suggest that definition of outcomes in
trials is a widespread problem[83]. The studies set
(sometimes arbitrary) criteria regarding when the patient
stay started, including “from study entry, which was
within 12 h of admission” (n = 2) [20, 62]; from hospital
admission (n = 3) [65, 68, 73]; or from first dose of study
medication (n = 2)[70, 71]; information was absent for the
remaining 11 studies [18, 19, 25–27, 63, 64, 66, 67, 69, 72].
The reported time to entry into study varied from 3 to
24 h, and generally did not specify whether “entry” corre-
sponded to consent or first treatment. The latter criterion
in particular represents a huge proportion of an admis-
sion in units with mean stays of 72 h or less. Similarly,
discharge was defined and assessed differently across
studies. In one study the discharge assessment used a
continuous discharge criteria [73],but in at least five
others the decision to discharge was made only once a
day [18, 19, 63, 65, 66], meaning the time of discharge is
effectively a discrete outcome which occurs at intervals
of 24 h. Although this inevitably overestimates the real
time taken to be fit for discharge, it does so equally for
both groups and would be expected to underestimate
rather than overestimate the difference between the
groups. With this in mind we have no explanation for
why the positive studies are based on a once daily clin-
ical assessment.
In the remaining studies the frequency of assessment
for discharge was unclear. We present a summary of the
discharge criteria in Additional file 10.
The criteria for discharge range from saturating 92 % or
greater in air & oral feeding >75 % of usual intake [73] to
no respiratory signs or symptoms for the previous 12 h
[63, 64]. As may be expected, stricter criteria leads to
longer LoS. The criteria that patients should be free of any
signs or symptoms is curious as it has been well docu-
mented that the symptoms associated with acute bron-
chiolitis persists for many days or even weeks [73, 84].
Behrendt et al. previously noted a marked variation in
length of stay of patients admitted with RSV bronchiolitis
with very short admissions [median approx. 72 h] in USA,
UK and Northern Europe as compared with significantly
longer admissions in Germany and Southern Europe [85]
a finding corroborated by more recent trials that have
been included herein. These longer admissions were asso-
ciated with increased co-morbidities such as diarrhoea
which may be as a result of nosocomial infection resulting
from longer admission times. This cultural difference is
again noted with none of the Italian subjects in the study
of Giudice being discharged before 72 h, a period beyond
the mean ‘length of stay’ in the Dutch, UK and USA study
[70, 73, 85]. Finally, the subjects in the Luo studies with
mild to moderate [63] bronchiolitis remained in hospital
longer than those with more severe disease [64], a finding
which is somewhat difficult to explain.
iii)Publication, generalisability and other biases
This difference in practice may also, in large part, explain
the differences in observed treatment effects in the large
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UK, Dutch and USA studies which found no benefit as
compared with the apparently large effect observed in
other studies [70, 71, 73]. While early indications of a
potential benefit may have been attributable to publication
bias [86, 87] the positive effects of later large studies may
be attributable to study design and cultural effects. It is of
note that all the recent studies of hypertonic saline have
failed to demonstrate any benefit yet the ‘meta-analysis still
appears to favour the treatment. This effect is largely
driven by the relatively large studies of Luo et al. and it is
likely that this is explicable when considering discharge
criteria in more detail (see above).
In summary therefore, there remains considerable het-
erogeneity which are not germane to being captured and
quantified by standard meta-regression tools. Clearly, a
large amount of the heterogeneity is driven by two trials
from the same team, led by Luo [63, 64], with outlying re-
sults, relatively small sample sizes but narrow confidence
intervals (around a day, compared with a day-and-a-half
in SABRE [73] and the other large northern European
study—Teunissen 2014 [70]). The removal of these two
studies from the main analysis considerably reduces the
effect sizes and statistical significance in the analyses to a
more modest (and minimal) impact. Nevertheless, this
does not eliminate heterogeneity completely.
Finally, there choice whether to favour a fixed- or
random-effects analysis remains open to debate, with
strong and apparently compelling proponents on both
sides [32, 88–91]. The presence of unexplained heterogen-
eity goes against the assumption of a single underlying
(fixed) effect, and this is commonly taken to justify the
random effect model. When the heterogeneity is excessive
however, the random effect model has the unfortunate
operational characteristic of allocating similar weights to
all trials, irrespective of their size and precision. Our deci-
sion to pre-specify a fixed-effect as the primary analysis
was taken to counter this limitation. That said, we are
unable to offer a clinically sensible reason why the largest
trial should be allocated only 4 % of the weight in this ana-
lysis. Given this, together with the large and unexplained
heterogeneity in general, our recommendation is that no
single overall summary measure—fixed, random or other-
wise—is an adequate reflection of the identified trials.
Although we investigated response in relation to dose (3,
5 or 6 %), the studies did not provide data on frequency or
duration of HS, which may also have varied across studies.
Strengths and limitations compared to other reviews
Building on the review conducted by Zhang and col-
leagues which contained 11 RCTs (n = 1090), our re-
view included 15 trials (n = 1922) which included three
much larger trials which unanimously showed null results
[65, 70, 73]. We limited our inclusion criteria to trials of
inpatient infants, whereas Zhang et al. also included
outpatient and emergency department trials. Al-Ansari
has been included in our review despite being included in
the emergency department group by Zhang and col-
leagues, as the length of stay infers that the patients were
admitted [68]. Despite this, our meta-analysis included a
further 8 trials [25, 65–67, 70–73] which altogether
unearthed significantly higher levels of heterogeneity than
that stated in the previous Cochrane review. A potential
explanation is that we applied no restrictions in terms of
dose or way the intervention was administered, and in
addition we included data from one unpublished study:
Zhang et al. made no statement in regards to these.
Duplication is not without merit—it enables the replic-
ability of methods to be demonstrated, as well as adding
weight to or disputing the current evidence base [92–94].
Even when faced with identical data, approaches taken and
interpretations made can differ between researchers [95].
A well-defined rationale for any such duplicate review, as
required by the PRISMA checklist (though not explicitly)
[94], provides transparency regarding overlaps and subse-
quently, allows for informed debate about its value to the
evidence base [95].
Implications for policy and practice
The disparities between the results of the largest, most
precise trials and all the included trials, together with high
levels of heterogeneity, mean that neither individual trials
nor pooled estimates provide a firm evidence-base for the
use of hypertonic saline in inpatient acute bronchiolitis
[34]. The refutation of initially large treatment effects in
small trials by larger trials stronger is a phenomenon
which is observed more widely and should not surprise
the reader [96]. For instance, in the treatment of acute
bronchiolitis, initial evidence supporting the use of β2-
agonists has also been overturned as successive trials have
been published [97].
Further research
Our aggregate level data analysis was unable to identify
specific settings and characteristics which influence the ef-
fect of HS on LoS. Systematic sensitivity analyses, ideally
based on individual patient data and regression analyses
are warranted to better understand why hypertonic saline
showed substantial benefit in some trials yet none in others
[34]. In the absence of this, there is no robust evidence to
support the use of hypertonic saline.
Conclusions
Claims that hypertonic saline achieves small reductions
in LoS must be treated with scepticism based on the
15 known trials of HS. The findings appear at best
highly dependent on trial design and local policies. We
cannot rule out the possibility that inhaled HS offers
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symptomatic relief but have no data to support or deny
this possibility.
Additional files
Additional file 1: PROSPERO registration. (PDF 109 kb)
Additional file 2: PRISMA statement. (DOCX 24 kb)
Additional file 3: Search strategies. (DOCX 20 kb)
Additional file 4: ORBIT classification outcome matrix. (DOCX 16 kb)
Additional file 5: Excluded studies at full paper review stage.
(DOCX 20 kb)
Additional file 6: Study characteristics. (DOCX 43 kb)
Additional file 7: Clinical issues. (DOCX 34 kb)
Additional file 8: Risk of bias. (DOCX 21 kb)
Additional file 9: Adverse events narrative. (DOCX 22 kb)
Additional file 10: Discharge criteria. (DOCX 18 kb)
Competing interests
The authors declare that they have no completing interests.
Authors’ contributions
CM participated in the design and conception of the systematic review,
designed data collection tools, coordinated and conducted the data
collection, contributed to the analysis, interpretation of the results and
drafted the manuscript. HC coordinated and conducted the data collection,
contributed to the analysis and drafted the manuscript. DH participated in
the design and conception of the systematic review, coordinated and
conducted the data collection, contributed to the analysis, interpretation of
the results and drafted the manuscript. MB participated in statistical analyses,
interpretation of the results and drafted the manuscript. MLE contributed to
the analysis, interpretation of the results and drafted the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
No specific funding supported the initial work on this review, however revisions
to the work were undertaken during the write-up of the Hypertonic Saline in
Acute Bronchiolitis: Randomised Controlled Trial and Economic Evaluation
(SABRE). This project was funded by the Health Technology Assessment
programme (HTA 09/91/22) and will be published in full in the Health
Technology Assessment journal series. Further information available at:
http://www.nets.nihr.ac.uk/projects/hta/099122. This report presents
independent research commissioned by the NIHR. The views and opinions
expressed by authors in this publication are those of the authors and do
not necessarily reflect those of the NHS, the NIHR, MRC, CCF, NETSCC, the
Health Technology Assessment programme or the Department of Health.
The Authors gratefully acknowledge the contribution of unpublished data
by Bettina Loza of the VieCuri Medisch Centrum voor Noord Limburg,
Venlo, The Netherlands and Alyssa Silver of The Children’s Hospital of
Montefiore, Bronx, New York.
Author details
1Clinical Trials Research Unit, University of Sheffield, Sheffield, UK. 2School of
Paediatrics and Child Health (SPACH), The University of Western Australia,
Perth, Australia.
Received: 25 June 2015 Accepted: 10 November 2015
References
1. Elliot S, Ray C. Viral infections of the lower respiratory tract. In: Taussig L,
Landau L, editors. Pediatric respiratory medicine. 2nd edition. Philadelphia:
MosbyElsevier; 2009. p. 481–90.
2. Everard M. Respiratory syncytial virus bronchiolitis and pneumonia. In:
Taussig L, Landau L, editors. Paediatric respiratory medicine. 2nd edition.
St Louis: Mosby; 2009.
3. Smyth RL, Openshaw PJM. Bronchiolitis. Lancet. 2006;368:312–22.
4. Scottish Intercollegiate Guidelines Network SIGN. Bronchiolitis in children - a
national clinical guideline [http://www.sign.ac.uk/pdf/sign91.pdf]
5. Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis
and management of bronchiolitis. Pediatrics. 2006;118:1774–93.
6. Deshpande SA, Northern V. The clinical and health economic burden of
respiratory syncytial virus disease among children under 2 years of age in a
defined geographical area. Arch Dis Child. 2003;88:1065–9.
7. Martin AJ, Gardner PS, Mcquillin J. Epidemiology of respiratory viral infection
among paediatric inpatients over a six-year period in North-East England.
Lancet. 1978;312:1035–8.
8. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al.
The burden of respiratory syncytial virus infection in young children. N Engl
J Med. 2009;360:588–98.
9. Murray J, Bottle A, Sharland M, Modi N, Aylin P, Majeed A, et al. Risk factors
for hospital admission with RSV bronchiolitis in England: A population-
based birth cohort study. PLoS One. 2014;9:e89186.
10. Centers for Disease Control and Prevention (CDC). Respiratory Syncytial
Virus Activity - United States, July 2008-December 2009 [http://www.cdc.
gov/mmwr/preview/mmwrhtml/mm5908a4.htm]
11. Fleming DM, Elliot AJ, Cross KW. Morbidity profiles of patients consulting
during influenza and respiratory syncytial virus active periods. Epidemiol
Infect. 2007;135:1099–108.
12. Elliot AJ, Fleming DM. Influenza and respiratory syncytial virus in the elderly.
Expert Rev Vaccines. 2008;7:249–58.
13. Falsey A, Hennessey P, Formica M, Cox C, Walsh E. Respiratory syncytial virus
infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749–5.
14. Reynolds E, Cook C. The treatment of bronchiolitis. J Pediatr. 1963;63:1205–7.
15. Panickar JR, Dodd SR, Smyth RL, Couriel JM. Trends in deaths from
respiratory illness in children in England and Wales from 1968 to 2000.
Thorax. 2005;60:1035–8.
16. Fleming DM, Pannell RS, Cross KW. Mortality in children from influenza
and respiratory syncytial virus. J Epidemiol Community Health. 2005;59:
586–90.
17. Sarrell EM, Tal G, Witzling M, Someck E, Houri S, Cohen HA, et al. Nebulized
3 % hypertonic saline solution treatment in ambulatory children with viral
bronchiolitis decreases symptoms. Chest. 2002;122:2015–20.
18. Mandelberg A, Tal G, Witzling M, Someck E, Houri S, Balin A, et al. Nebulized
3 % hypertonic saline solution treatment in hospitalized infants with viral
bronchiolitis. Chest. 2003;123:481–7.
19. Tal G, Cesar K, Oron A, Houri S, Ballin A, Mandelberg A. Hypertonic
saline/epinephrine treatment in hospitalized infants with viral
bronchiolitis reduces hospitalization stay: 2 years experience. ISR Med
Assoc J Imaj. 2006;8:169–73.
20. Kuzik BA, Al-Qadhi SA, Kent S, Flavin MP, Hopman W, Hotte S, et al.
Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants.
J Pediatr. 2007;151:266–70.
21. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic
saline solution for acute bronchiolitis in infants. Cochrane Database Syst
Rev. 2013;7:CD006458.
22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: The PRISMA statement. PLoS Med.
2009;6:e1000097.
23. Chin Maguire, Hannah Cantrill. Nebulised hypertonic saline solution for
acute bronchiolitis in infants: a systematic review and meta-analysis.
PROSPERO 2014:CRD42014007569 Available from http://www.crd.york.ac.uk/
PROSPERO/display_record.asp?ID=CRD42014007569.
24. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulized hypertonic
saline solution for acute bronchiolitis in infants. Cochrane Database Syst
Rev. 2009;2011:CD006458. 2009Article Number CD006458Date Publ.
25. Efficacy of Nebulized Hypertonic Saline in the Treatment of Acute
Bronchiolitis (NCT01238848) [http://www.clinicaltrials.gov/ct2/show/
NCT01238848?term=espelt+bronchiolitis&rank=1]
26. Nebulized 3 % Hypertonic Saline Solution Treatment of Bronchiolitis in
Infants (NCT02233985) [https://clinicaltrials.gov/ct2/show/study/
NCT02233985?term=“Hypertonic+saline”+AND+“bronchiolitis”&lup_s=01/
03/2014&rank=8]
27. Ozdogan S, Koker O, Kose G, Yildirmak Y. The Efficacy Of Nebulized
Hypertonic Saline In AcuteBronchiolitis In Hospital Setting: A Randomized
And Double Blind Trial. Am J Respir Crit Care Med 2014;189(11): A2740. URL:
http://www.atsjournals.org/doi/abs/10.1164/ajrccmconference. 2014.189.1_
MeetingAbstracts.A2740.
Maguire et al. BMC Pulmonary Medicine  (2015) 15:148 Page 15 of 17
28. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al.
The Cochrane Collaboration’s tool for assessing risk of bias in randomised
trials. BMJ. 2011;343:d5928.
29. Wang EE, Milner RA, Navas L, Maj H. Observer agreement for respiratory
signs and oximetry in infants hospitalized with lower respiratory infections.
Am Rev Respir Dis. 1992;145:106–9.
30. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0
[updated March 2011] [www.cochrane-handbook.org]
31. Dwan K, Gamble C, Kolamunnage-Dona R, Mohammed S, Powell C,
Williamson PR. Assessing the potential for outcome reporting bias in a
review: A tutorial. Trials. 2010;11:52.
32. Egger M, Davey Smith G, Altman DG. Systematic reviews in health care: Meta-
analysis in context, second edition - Wiley online library. London: BMJ; 2001.
33. Advanced Statistical Methods to Model and Adjust for Bias in Meta-Analysis
[http://cran.r-project.org/web/packages/metasens/metasens.pdf]
34. Dechartres A, Altman DG, Trinquart L, Boutron I, Ravaud P. Association
between analytic strategy and estimates of treatment outcomes in
meta-analyses. JAMA. 2014;312:623.
35. Mandelberg A. Hypertonic saline in the treatment of acute bronchiolitis in
the emergency department. Arch Pediatr Adolesc Med. 2010;164:395–7.
36. Principi T, Komar L. A critical review of “a randomized trial of nebulized 3 %
hypertonic saline with epinephrine in the treatment of acute bronchiolitis in
the emergency department.”. J Popul Ther Clin Pharmacol. 2011;18:e273–4.
37. Hom J, Fernandes RM. When should nebulized hypertonic saline solution
be used in the treatment of bronchiolitis? Paediatr Child Health. 2011;16:
157–8. March.
38. Sauvaget E, David M, Bresson V, Retornaz K, Bosdure E, Dubus JC. Nebulized
hypertonic saline and acute viral bronchiolitis in infants: Current aspects].
[Review] [French. Arch Pediatr. 2012;19:635–41.
39. Ipek IO, Yalcin EU, Sezer RG, Bozaykut A. The efficacy of nebulized salbutamol,
hypertonic saline and salbutamol/hypertonic saline combination in moderate
bronchiolitis. Pulm Pharmacol Ther. 2011;24:633–7.
40. Anil AB, Anil M, Saglam AB, Cetin N, Bal A, Aksu N. High volume normal
saline alone is as effective as nebulized salbutamol-normal saline,
epinephrine-normal saline, and 3 % saline in mild bronchiolitis. Pediatr
Pulmonol. 2010;45:41–7.
41. Grewal S, Ali S, McConnell DW, Vandermeer B, Klassen TP. A randomized
trial of nebulized 3 % hypertonic saline with epinephrine in the treatment
of acute bronchiolitis in the emergency department. Arch Pediatr Adolesc
Med. 2009;163:1007–12.
42. Kuzik BA, Flavin MP, Kent S, Zielinski D, Kwan CW, Adeleye A, et al. Effect of
inhaled hypertonic saline on hospital admission rate in children with viral
bronchiolitis: A randomized trial. CJEM Can Emerg Med care. 2010;12:477–84.
43. Sezer GR, Bozaykut A, Ipek IO, Uyur E, Seren PL, Paketci C. The efficacy of
nebulized salbutamol, hypertonic saline and salbutamol / hypertonic saline
combination in first bronchiolitis attack. Acta Paediatr. 2010;99:153.
44. Jacobs JD, Foster M, Wan J, Pershad J. 7 % Hypertonic saline in acute
bronchiolitis: A randomized controlled trial. Pediatrics. 2014;133:e8–13.
45. Wu S, Baker C, Lang ME, Schrager SM, Liley FF, Papa C, Mira V, Balkian A,
Mason WH. Nebulized Hypertonic Saline for Bronchiolitis: A Randomized
Clinical Trial. JAMA Pediatr. 2014 Jul;168(7):657-63. doi: 10.1001/
jamapediatrics.2014.301. Erratum in: JAMA Pediatr. 2014 Oct;168 (10):971.
46. Gupta N, Puliyel A, Manchanda A, Puliyel J. Nebulized hypertonic-saline vs
epinephrine for bronchiolitis: Proof of concept study of cumulative sum
(CUSUM) analysis. Indian Pediatr. 2012;49:543–7. July.
47. Khashabi J, Salari LS, Karamiyar M, Mussavi H. Comparison of the efficacy
of nebulized L-epinephrine, salbutamol and normal saline in acute
bronchiolitis: A randomized clinical trial. Med J Islam Repub Iran.
2005;19:2005.
48. Lines DR, Bates ML, Rechtman AR, Sammartino LP. Efficacy of nebulised
ipratropium bromide in acute bronchiolitis. Pediatr Rev Commun.
1992;6:1992.
49. Milner A. The role of anticholinergic in acute bronchiolitis in infancy.
[French]. Arch Pediatr. 1995;2:159S–62S.
50. Patel H, Platt RW, Pekeles GS, Ducharme FM. A randomized, controlled trial
of the effectiveness of nebulized therapy with epinephrine compared with
albuterol and saline in infants hospitalized for acute viral bronchiolitis.
J Pediatr. 2002;141:818–24.
51. Tinsa F, Rhouma AB, Ghaffari H, Boussetta K, Zouari B, Brini I, et al. A randomized,
controlled trial of nebulized terbutaline in the first acute bronchiolitis in infant
less than 12 months old. Tunis Med. 2009;87:200–3. March.
52. Wainwright C, Altamirano L, Cheney M, Cheney J, Barber S, Price D, et al. A
multicenter, randomized, double-blind, controlled trial of nebulized
epinephrine in infants with acute bronchiolitis. N Engl J Med. 2003;349:27–35.
53. Postiaux G, Louis J, Labasse HC, Gerroldt J, Kotik AC, Lemuhot A, et al.
Evaluation of an alternative chest physiotherapy method in infants with
respiratory syncytial virus bronchiolitis. Respir Care. 2011;56:989–94.
54. Hariprakash S, Alexander J, Carroll W, Ramesh P, Randell T, Turnbull F, et al.
Randomized controlled trial of nebulized adrenaline in acute bronchiolitis.
Pediatr Allergy Immunol. 2003;14:134–9.
55. Chowdhury D, Al HM, Khalil M, Al-Frayh AS, Chowdhury S, Ramia S. The role
of bronchodilators in the management of bronchiolitis: A clinical trial. Ann
Trop Paediatr. 1995;15:77–84.
56. Nenna R, Tromba V, Berardi R, De AD, Papoff P, Sabbatino G, Moretti C, Midulla
F: Recombinant human deoxyribonuclease treatment in hospital management
of infants with moderate-severe bronchiolitis. Eur J Inflamm 2009;7:169–74.
57. Bertrand P, Aranibar H, Castro E, Sanchez I. Efficacy of nebulized
epinephrine versus salbutamol in hospitalized infants with bronchiolitis.
Pediatr Pulmonol. 2001;31:2001.
58. Nenna R, Papoff P, Moretti C, De Angelis D, Battaglia M, Papasso S,
Bernabucci M, Cangiano G, Petrarca L, Salvadei S, Nicolai A, Ferrara M,
Bonci E, Midulla F: Seven percent hypertonic saline-0.1 % hyaluronic acid
in infants with mild-to-moderate bronchiolitis. Pediatr Pulmonol.
2014;49:919–25.
59. Bueno Campaña M, Olivares Ortiz J, Notario Muñoz C, Rupérez Lucas M,
Fernández Rincón A, Patiño Hernández O, Calvo Rey C: High flow therapy
versus hypertonic saline in bronchiolitis: randomised controlled trial. Arch
Dis Child 2014;99(6):511-5. doi: 10.1136/archdischild-2013-305443.
60. Park JY, Jeong YM, Jeong SJ, Seo SS. The efficacy of nebulized 3 percent
hypertonic saline solution and fenoterol in infants with bronchiolitis. Korean
J Pediatr. 2005;48:518–22.
61. Zheng W, Li L, Chengfung H, Yunmei H, Wei L. The effects of inhalation of
the 3 % hypertonic saline solution with ambroxol hydrochloride in the
treatment of 43 bronchiolitis patients. J Pediatr Pharm. 2012;18.
62. Giudice M, Saitta F, Leonardi S, Capasso M, Niglio B, Chinellato I, et al.
Effectiveness of nebulized hypertonic saline and epinephrine in hospitalized
infants with bronchiolitis. Int J Immunopathol Pharmacol. 2012;25:485–91.
63. Luo Z, Liu E, Luo J, Li S, Zeng F, Yang X, et al. Nebulized hypertonic saline/
salbutamol solution treatment in hospitalized children with mild to
moderate bronchiolitis. Pediatr Int. 2010;52:199–202.
64. Luo Z, Fu Z, Liu E, Xu X, Fu X, Peng D, et al. Nebulized hypertonic saline
treatment in hospitalized children with moderate to severe viral bronchiolitis.
Clin Microbiol Infect Off Eur Soc Clin Microbiol Infect. 2011;17:1829–33.
65. Sharma BS, Gupta MK, Rafik SP. Hypertonic (3 %) saline vs 0.9 % saline
nebulization for acute viral bronchiolitis: A randomized controlled trial.
Indian Pediatr. 2013;50:743–7.
66. Pandit S, Dhawan N, Thakur D. Utility of hypertonic saline in the
management of acute bronchiolitis in infants: A randomised controlled
study. Int J Clin Pediatr. 2013;2:24–9.
67. Maheshkumar KB, Karunakara BP, Nagalli MM, Mallikarjuna HB: Aerosolised
hypertonic saline in hospitalized young children with acute bronchiolitis:
a randomized controlled clinical trial. Journal of Pediatric Sciences
(ISSN:1309–1247) 2013.
68. Al-Ansari K, Sakran M, Davidson BL, El SR, Mahjoub H, Ibrahim K. Nebulized
5 % or 3 % hypertonic or 0.9 % saline for treating acute bronchiolitis in
infants. J Pediatr. 2010;157:630–4.
69. Nebulized 3 % hypertonic saline in the treatment of acute bronchiolitis in
infants. [http://www.ersnet.org/learning_resources_player/abstract_print_13/
files/Abstract_book_2013.pdf]
70. Teunissen J, Hochs AHJ, Vaessen-Verberne A, Boehmer ALM, Smeets CCJM,
Brackel H, et al. The effect of 3% and 6% hypertonic saline in viral
bronchiolitis: A randomised controlled trial. Eur Respir J. 2014;44(4):913–21.
71. A Study of Hypertonic Saline for Infants Hospitalized With Bronchiolitis
(NCT01488448) [https://clinicaltrials.gov/ct2/show/NCT01488448]
72. Ojha A, Mathema S, Sah S, Aryal U. A comparative study on use of 3 %
saline versus 0.9 % saline nebulisation in children with bronchiolitis. J Nepal
Heal Res Counc. 2014;12:39–43.
73. Everard ML, Hind D, Ugonna K, Freeman J, Bradburn M, Cooper CL, et al.
SABRE: A multicentre randomised control trial of nebulised hypertonic saline in
infants hospitalised with acute bronchiolitis. Thorax. 2014;69:1105–12.
74. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects
meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172:137–59.
Maguire et al. BMC Pulmonary Medicine  (2015) 15:148 Page 16 of 17
75. Baujat B, Mahé C, Pignon J, Hill C. A graphical method for exploring
heterogeneity in meta-analyses: Application to a meta-analysis of 65 trials.
Stat Med. 2002;30:2641–52.
76. Rucker G, Carpenter J, Schwarzer G. Detecting and adjusting for small-study
effects in meta-analysis. Biom J. 2011;53:351–68.
77. Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, et al. The
effect of English-language restriction on systematic review-based meta-analyses:
A systematic review of empirical studies. Int J Technol Assess Health Care.
2012;28:138–44.
78. Elphick H, Everard M. Noisy breathing in children. In: David T, editor. Recent
advances in paediatrics. London: The Royal Society of Medicine; 2002.
79. Elphick H, Ritson S, Rodgers H, Everard M. When a “Wheeze” is not a
wheeze: Acoustic analysis of breath sounds in infants. Eur Respir J.
2000;16:593–7.
80. Elphick HE, Lancaster GA, Solis A, Majumdar A, Gupta R, Smyth RL. Validity
and reliability of acoustic analysis of respiratory sounds in infants. Arch Dis
Child. 2004;89:1059–63.
81. Pasterkamp H. Nomenclature used by health care professionals to describe
breath sounds in asthma. CHEST J. 1987;92:346.
82. Spiteri MA, Cook DG, Clarke SW. Reliability of eliciting physical signs in
examination of the chest. Lancet. 1988;1:873–5.
83. Moustgaard H, Bello S, Miller FG, Hróbjartsson A. Subjective and objective
outcomes in randomized clinical trials: Definitions differed in methods
publications and were often absent from trial reports. J Clin Epidemiol.
2014;67:1327–34.
84. Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice M-P, et al.
Study of montelukast for the treatment of respiratory symptoms of
post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit
Care Med. 2008;178:854–60.
85. Behrendt CE, Decker MD, Burch DJ, Watson PH. International variation in the
management of infants hospitalized with respiratory syncytial virus. Int RSV
Study Group Eur J Pediatr. 1998;157:215–20.
86. Rosenthal R. The file drawer problem and tolerance for null results. Psychol
Bull. 1979;86:638–41.
87. Dickersin K. The existence of publication bias and risk factors for its
occurrence. JAMA. 1990;263:1385–9.
88. Hunter JE, Schmidt FL. Fixed effects vs. random effects meta-analysis
models: Implications for cumulative research knowledge. Int J Sel Assess.
2000;8:275–92.
89. Greenland S. Quantitative methods in the review of epidemiologic
literature. Epidemiol Rev. 1987;9:1–30.
90. Peto R. Why do we need systematic overviews of randomized trials? Stat
Med. 1987;6:233–40.
91. Thompson SG, Pocock SJ. Can meta-analyses be trusted? Lancet. 1991;338:
1127–30.
92. Siontis KC, Hernandez-Boussard T, Ioannidis JPA. Overlapping meta-analyses
on the same topic: Survey of published studies. BMJ. 2013;347:f4501.
93. Garritty C, Tsertsvadze A, Tricco AC, Sampson M, Moher D. Updating
systematic reviews: An international survey. PLoS One. 2010;5:e9914.
94. Moher D. The problem of duplicate systematic reviews. BMJ. 2013;347:f5040.
95. Krumholz H. The case for duplication of meta-analyses and systematic
reviews. BMJ. 2013;347:f5506.
96. Ioannidis JPA. Contradicted and initially stronger effects in highly cited
clinical research. JAMA. 2005;294:218–28.
97. Schroeder AR, Mansbach JM. Recent evidence on the management of
bronchiolitis. Curr Opin Pediatr. 2014;26:328–33.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Maguire et al. BMC Pulmonary Medicine  (2015) 15:148 Page 17 of 17
